Dicks Sporting Goods Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Dicks Sporting Goods Inc trades at $206.29 (market cap $18.35B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.3× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| DKS | VRTX | |
|---|---|---|
Market Cap | $18.35B | $134.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $529.65 |
52-Week Low | $187.78 | $376.62 |
Enterprise Value | $25.14B | $128.37B |
Dividend Yield | 2.44% | — |
Trailing returns across standard periods
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →